Apoptosis in normal rectal mucosa, baseline adenoma characteristics, and risk of future adenomas

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 2, 2008, Pages 306-310

  Keku, Temitope O ^a,b   Amin, Ahmad ^a   Galanko, Joseph ^a   Martin, Christopher ^a   Schliebe, Barbara ^a   Sandler, Robert S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER RISK; COLONOSCOPY; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECTUM ADENOMA; RECTUM BIOPSY; RECTUM MUCOSA; TUMOR VOLUME;

ADENOMA; ANALYSIS OF VARIANCE; APOPTOSIS; BIOPSY; CASE-CONTROL STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IN SITU NICK-END LABELING; INTESTINAL MUCOSA; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 39449109726     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0066     Document Type: Article

References (32)

1. Fenoglio CM, Lane N. The anatomical precursor of colorectal carcinoma. Cancer 1974;34 suppl:819-23.
2. van Stolk RU, Beck GJ, Baron JA, Haile R, Summers R; The Polyp Prevention Study Group. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. Gastroenterology 1998;115:13-8.
3. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993;328:901-6.
4. Martinez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, Alberts DS. Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology 2001;120:1077-83.
5. Bonithon-Kopp C, Piard F, Fenger C, et al. Colorectal adenoma characteristics as predictors of recurrence. Dis Colon Rectum 2004;47:323-33.
6. Avidan B, Sonnenberg A, Schnell TG, Leya J, Metz A, Sontag SJ. New occurrence and recurrence of neoplasms within 5 years of a screening colonoscopy. Am J Gastroenterol 2002;97:1524-9.
7. Martin C, Connelly A, Keku TO, et al. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology 2002;123:1770-7.
8. McDonnell TJ. Cell division versus cell death: a functional model of multistep neoplasia. Mol Carcinog 1993;8:209-13.
9. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
10. Butler LM, Hewett PJ, Fitridge RA, Cowled PA. Deregulation of apoptosis in colorectal carcinoma: theoretical and therapeutic implications. Aust N Z J Surg 1999;69:88-94.
11. Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis. Am J Surg 2006;191:517-26.
12. Rupnarain C, Dlamini Z, Naicker S, Bhoola K. Colon cancer: genomics and apoptotic events. Biol Chem 2004;385:449-64.
13. Sjostrom J, Bergh J. How apoptosis is regulated, and what goes wrong in cancer. BMJ 2001;322:1538-9.
14. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-6.
15. Anti M, Armuzzi A, Morini S, et al. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 2001;48:238-46.
16. Connelly AE, Satia-Abouta J, Martin CF, et al. Vitamin C intake and apoptosis in normal rectal epithelium. Cancer Epidemiol Biomarkers Prev 2003;12:559-65.
17. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
18. Arai T, Kino I. Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas. J Pathol 1995;176:37-44.
19. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996;56:2422-7.
20. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 1996;93:7950-4.
21. Moss SF, Scholes JV, Holt PR. Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyuridine nick end labeling. Dig Dis Sci 1996;41:2238-47.
22. Sinicrope FA, Half E, Morris JS, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2004;13:920-7.
23. Keller JJ, Offerhaus GJ, Polak M, et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 1999;45:822-8.
24. Mahmoud NN, Boolbol SK, Dannenberg AJ, et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998;19:87-91.
25. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-8.
26. Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2004:CD004079.
27. Hartman TJ, Yu B, Albert PS, et al. Does nonsteroidal antiinflammatory drug use modify the effect of a low-fat, high-fiber diet on recurrence of colorectal adenomas? Cancer Epidemiol Biomarkers Prev 2005;14:2359-65.
28. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006;355:950-2.
29. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998;114:441-7.
30. Chang WC, Everley LC, Pfeiffer GR II, Cooper HS, Barusevicius A, Clapper ML. Sulindac sulfone is most effective in modulating β-catenin-mediated transcription in cells with mutant APC. Ann N Y Acad Sci 2005;1059:41-55.
31. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997;57:2452-9.
32. Neugut AI, Jacobson JS, Ahsan H, et al. Incidence and recurrence rates of colorectal adenomas: a prospective study. Gastroenterology 1995;108:402-8.